Introduction {#S1}
============

Thyroid cancer (TC) is the most common endocrine cancer malignancy worldwide ([@B1]) with a rising incidence in particular among young patients and women ([@B2]--[@B4]). Overdiagnosis of subclinical disease, previously proposed as a contributor for the rising incidence, cannot explain the full extent of the increase ([@B5], [@B6]). Risk factors such as exposure to ionizing radiation ([@B7]--[@B10]), chemical genotoxins ([@B11]--[@B13]), and obesity ([@B14]--[@B17]), as well as a lack of protective factors, such as vitamin D deficiency have been implicated in TC increased incidence ([@B18]--[@B21]).

Vitamin D, an active ingredient of cod-liver oil, was first identified as a cure for rickets in the nineteenth century and has emerged as a principal regulator of calcium homeostasis ([@B22]). Cutaneous exposure to sun and dietary intake are the two main natural sources of vitamin D. Vitamin D activity depends on metabolic activation through hydroxylation of the 25 followed by the 1 position of the molecule by cytochromes P450s, which generate the biologically active metabolite 1,25(OH)~2~D3. The action of vitamin D occurs mainly through its binding to the nuclear vitamin D receptor (VDR), which acts as a hormone-regulated transcription factor ([@B23]). Upon activation, the VDR forms a heterodimer with related retinoid-X receptors and binds to vitamin D response elements (VDREs) on chromatin regions resulting in the regulation of the expression of several target genes ([@B24]--[@B26]). VDRE binding by the VDR provides the principle mechanism by which the receptor can activate gene transcription. However, the hormone-bound receptor can also repress gene transcription by a variety of mechanisms ([@B27]). Downstream targets of the receptor are involved in mineral metabolism, but VDR also regulates a variety of other metabolic pathways, many of which are components of immune response and cancer signaling ([@B28], [@B29]).

Independent studies support that circulating levels of vitamin D are inversely correlated to several malignancies, including colorectal cancer ([@B30], [@B31]), prostate cancer ([@B32]), breast cancer ([@B33], [@B34]), and head and neck squamous cell carcinoma ([@B35], [@B36]). As well, a more recent meta-analysis reported a correlation between vitamin D deficiency and poorer prognosis in several tumor types ([@B37]). In TC, several studies point toward a role for impaired 1,25(OH)~2~D3-VDR signaling in the occurrence and progression of the disease ([@B38]). This review addresses new insights into genetic and epigenetic determinants of vitamin D response in relation to cancer risk focusing on TC. We provide a systematic review and analysis of experimental and clinical data and the impact of genome-wide analyses on individual susceptibility to TC.

Materials and Methods {#S2}
=====================

Genomic database {#S2-1}
----------------

The UCSC Cancer Genomics Browser ([@B39]), a set of web-based tools to display, was used to investigate and analyze cancer genomics data and its clinical information associated with VDR. The browser provides whole-genome to base-pair level views of several different types of genomic data, including next-generation sequencing platforms. Biological pathways, collections of genes, genomic or clinical information were used to sort, aggregate, and zoom into a group of samples. The current release (2013) displays an expanding set of data from various sources, including 201 datasets from 22 The Cancer Genome Atlas (TCGA) cancers as well as data from Cancer Cell Line Encyclopedia and Stand Up To Cancer ([@B39]).

Database of somatic mutations {#S2-2}
-----------------------------

To collect data on TC related to VDR mutation, the web-software BioMart Central Portal and the Catalog of Somatic Mutations in Cancer (COSMIC) database ([@B40]) were used. BioMart offers a one-stop shop solution to access a wide array of biological databases, such as the major biomolecular sequence, pathway, and annotation databases such as Ensembl, Uniprot, Reactome, HGNC, Wormbase, and PRIDE ([@B41]). The Cancer BioMart web-interface with the following criteria was used: (1) Primary site = "thyroid"; (2) Mutation ID is not empty. The first criterion ensures that the mutation occurs in thyroid tissues, and the second criterion helps to exclude the samples without mutation in a specific gene. Thereby, we obtained the list of mutations in TC.

Catalog of Somatic Mutations in Cancer ([@B40]) stores and displays somatic mutation information and related details on human cancers. COSMIC was developed, and is currently maintained, at the Welcome Trust Sanger Institute. It is designed to gather, curate, and organize information on somatic mutations in cancer and to make it freely available on-line. It combines cancer mutation data, manually curate from the scientific literature, with the output from the Cancer Genome Project (CGP). Genes are selected for full literature curation using the Cancer Gene Census. The current release (v64) describes over 913,166 coding mutations of 24,394 genes from almost 847,698 tumor samples. All genes selected for the COSMIC database came from studies in the literature and are somatically mutated in human cancer ([@B42]). Based on this authority resource, a dataset of TC mutation was constructed.

Data extraction {#S2-3}
---------------

Information was carefully extracted from all eligible publications including clinical and experimental studies assessing any relation between vitamin D and non-medullary TC. A search for studies in the electronic databases Ovid Medline, Ovid Embase, Web of Science, AMED, and the Cochrane Library was run using an elaborated search strategy (Supplemental Material). In order not to miss any appropriate study, no time or language limits were applied for the search. Review articles were included only temporarily to provide a manual search tool.

The selection of studies involved an initial screening of the title and the abstract. In doubtful cases, the full text was obtained. Articles were entered in the data management software and the duplicates were eliminated (Endnote 6^®^, Thomson Reuters Inc.). For clinical studies, detailed information about participants (number of patients, study location(s), and demographics variables), exposure (sun irradiation, dietary intake, and vitamin D serum level), comparison group, and outcome was assessed.

The search retrieved 471 references published until July 4th, 2013, 12 from the Cochrane Library, 176 from Ovid Medline, 188 from Ovid Embase and AMED, and 95 from Web of Sciences. Crosschecking the references of the reviews led to the inclusion of four supplementary articles ([@B43]--[@B46]). No clinical trial was available. The flow chart of study selection is shown in Figure [1](#F1){ref-type="fig"}.

![**Flow chart of study selection for systematic review**.](fonc-04-00309-g001){#F1}

Overall 30 articles were included, of which 17 were clinical studies (Table [1](#T1){ref-type="table"}) and 13 experimental studies (Table [2](#T2){ref-type="table"}). These studies were published in English language from 1987 to 2013. Of the 17 clinical studies, 8 (47.0%) showed protective effect of vitamin D ([@B44], [@B45], [@B47]--[@B52]), 6 (35.3%) no significant relationship ([@B43], [@B46], [@B53]--[@B57]), and 2 (11.7%) revealed an increased TC risk with high vitamin D intake ([@B58], [@B59]). No comparison could be drawn from the remaining study (5.8%) ([@B60]). TC incidence was assessed in all of these studies, mortality in two ([@B45], [@B47]); and one report assessed both ([@B45]). Except for three studies involving Arab populations ([@B51], [@B56], [@B60]), all studies included Europeans' descendants and/or Hispanic whites.

###### 

**Summary of clinical studies reporting an association between thyroid cancer and vitamin D**.

  First author              Pub year   Country (state/province)[^a^](#tfn1){ref-type="table-fn"}   Cases/controls    Outcome                   Exposure                               Results[^b^](#tfn2){ref-type="table-fn"}
  ------------------------- ---------- ----------------------------------------------------------- ----------------- ------------------------- -------------------------------------- ------------------------------------------
  Akslen ([@B44])           1998       Norway                                                      2627/NA           Incidence                 Seasonal variation                     pro
  Boscoe ([@B45])           2006       USA                                                         \>4,000/\>4,000   Incidence and mortality   Latitude                               pro[^c^](#tfn3){ref-type="table-fn"}
  D'avanzo ([@B53])         1997       Italy                                                       399/617           Incidence                 Intake                                 NS
  Glattre ([@B54])          1993       Norway                                                      92/460            Incidence                 Intake                                 NS
  Grant ([@B47])            2006       Spain                                                       NR                Mortality                 Latitude                               pro
  Greenlee ([@B58])         2004       USA (WA)                                                    305/64,226        Incidence                 Intake                                 con
  Haghpanah ([@B56])        2007       Iran                                                        71/82             Incidence                 VDR polymorphism                       NS
  Jonklass ([@B46])         2013       USA (DC)                                                    48/17             Incidence                 Serum 25(OH)D                          NS
  Laney ([@B55])            2010       USA (NE)                                                    24/42             Incidence                 Serum 25(OH)D                          NS
  Mack ([@B43])             2002       USA (CA)                                                    292/292           Incidence                 Intake                                 NS
  Penna-Martinez ([@B48])   2009       Germany                                                     147/57            Incidence                 Serum 1,25(OH)~2~ D VDR Polymorphism   pro
  Penna-Martinez ([@B49])   2012       Germany                                                     253/302           Incidence                 Serum 1,25(OH)~2~ D                    pro
  Peterson ([@B60])         2011       USA (MI)                                                    30/70             NA                        Sun exposure                           NA
  Ron ([@B59])              1987       USA (CT)                                                    159/285           Incidence                 Intake                                 con
  Roskies ([@B50])          2012       Canada (QC)                                                 12/88             Incidence                 Serum 25(OH)D                          pro
  Sahin ([@B51])            2013       Turkey                                                      344/116           Incidence                 Serum 25(OH)D                          pro
  Stepien ([@B52])          2010       Poland                                                      50/26             Incidence                 Serum 1,25(OH)~2~ D                    pro

^a^WA, Washington; DC, District of Columbia; NE, Nebraska; CA, California; MI, Michigan; CT, Connecticut; QC, Quebec;

^b^pro, protective effect of vitamin D (or surrogates); NS, not significant; con, vitamin D (or surrogates) increasing risk; NA, not applicable;

*^c^for women only*.

###### 

**Experimental studies using cell lines or preclinical models to assess vitamin D effect on thyroid cancer**.

  First author           Pub year   Samples[^a^](#tfn4){ref-type="table-fn"}   Main results
  ---------------------- ---------- ------------------------------------------ --------------------------------------------------------------------------------------------
  Balla ([@B61])         2011       6 PTC                                      Overexpression of CYP24A1 mRNA
  Bennett ([@B62])       2012       TPC1, C643                                 Antiproliferative effect of calcitriol
  Clinckspoor ([@B63])   2011       FTC133, C643, 8505c, Hth74                 Antiproliferative effect of calcitriol and superagonistic analog CD578
  Clinckspoor ([@B64])   2012       64 thyroid cancers                         VDR, CYP24A1, CYP27B1 overexpression
  Dackiw ([@B65])        2004       15 SCID mice/WRO                           Growth inhibition of orthotopic tumor and p27^kip1^ restoration after calcitriol treatment
  Khadzkou ([@B66])      2006       44 PTC                                     Overexpression of VDR and CYP27B1 (FFPE)
  Liu ([@B67])           2002       NPA, WRO                                   Antiproliferative effect of calcitriol and superagonistic analog EB1089, p27 restoration
  Liu ([@B68])           2005       WRO                                        Calcitriol and its analog EB1089 restore PTEN-dependent fibronectin expression
                                    SCID mice/WRO                              Growth inhibition in heterotopic model with calcitriol and EB1089
  Liu ([@B69])           2011       WRO, MRO                                   Calcitriol inhibits CEACAM1
  Okano ([@B70])         1999       Nude mice/NPA                              Trend to growth inhibition in heterotopic model with calcitriol and less-calcemic analog
                                    NPA                                        Dose-dependent inhibition of calcitriol and less-calcemic analog
  Sharma ([@B71])        2010       TPC1, C643, Hth7, Hth74, 8505c, SW1736     Response to calcitriol/DP006 depending on VDR polymorphism and 24-hydroxylase levels
  Somjen ([@B72])        2013       NPA, ARO, MRO                              Overexpression of VDR and CYP27B1
  Suzuki ([@B73])        1999       TPC1-4, TAC1, TTA1                         Dose-dependent growth inhibition of calcitriol and less-calcemic analog

*^a^Cell line-corresponding histologic subtype: TPC1-4-PTC, KTC-PTC, BCPAP-PTC, NPA-PTC, KAT5-PTC, FTC133-FTC, FRO-FTC, MRO-FTC, WRO-FTC, C643-ATC, Hth7-ATC, Hth74-ATC, 8505c-ATC, SW1736-ATC, TAC-1-ATC, TTA-1-ATC. PTC, papillary thyroid cancer; FTC, follicular thyroid cancer; ATC, anaplastic thyroid cancer; SCID, severe combined immunodeficient*.

Results and Discussion {#S3}
======================

Determinants of vitamin D levels and impact in TC {#S3-4}
-------------------------------------------------

Solar UVB irradiation is the primary source of vitamin D and can be estimated by latitude of the living area. In TC, large epidemiological studies support an inverse relation between TC incidence and latitude ([@B45], [@B47]) (Table [1](#T1){ref-type="table"}). These studies performed a multivariate analysis to adjust for confounding factors. However, vitamin D levels were not measured. Consequently, it is unclear if the multivariate analysis resulted in accurate vitamin D estimates. Indeed, vitamin D deficiency is highly prevalent among latitudes that benefit from high solar irradiation such as Africa, the Middle East, and Southern Asia. This may be due to skin pigmentation, traditional clothing, and sun avoidance seen in southern heat-exposed populations ([@B60], [@B74]). In contrast, fair-skinned northern populations usually seek sun exposure and may also benefit from high intake of vitamin D rich diet such as fatty fish and cod-liver oil ([@B74]). Further, a mutation in the cutaneous structural protein filaggrin, which occurs in up to 10% of Europeans was shown to lead to higher circulating vitamin D levels ([@B75]). Nonetheless, North American and European studies have shown seasonal variations of vitamin D levels due to insufficient sun irradiation during winter ([@B76]). In TC, one study from Norway reported higher proliferation values for tumors resected during winter compared to other seasons ([@B44]). These results comply with above-mentioned studies showing an inverse relation between TC incidence and latitude ([@B45], [@B47]). For studies estimating vitamin D consumption and TC risk, however, no convincing associations have been shown (Table [1](#T1){ref-type="table"}) ([@B43], [@B53], [@B54], [@B58], [@B59]). This may be due to the general poor correlation between vitamin D deficiency and estimates of vitamin D consumption ([@B57]).

A more accurate way to assess vitamin D is biological monitoring. Association studies investigating the relationship between levels of serum vitamin D and TC risk mostly point toward a protective effect of vitamin D ([@B48]--[@B52], [@B55], [@B77]) (Table [1](#T1){ref-type="table"}). Pooling the data among these studies is not possible due to different cut-off levels for different vitamin D derivatives and control groups used in each of these studies. This would greatly limit the validity of a meta-analysis. The lack of consensus in cut-off levels may reflect the fact that those are differently defined depending on targeted clinical endpoints ([@B78], [@B79]). Classical vitamin D targets, i.e., those implicated in calcium and bone homeostasis, do not allow conclusions on optimal level of vitamin D having anticancer properties. While doses up to 4,000 IU of daily vitamin D supplementation have been considered safe, studies have reported hypercalcemia, nephrolithiasis, vascular, and soft tissue calcification with high doses of vitamin D and also U-shaped relationship between vitamin D levels above 75 nmol/l and certain cancer subtypes ([@B80], [@B81]). One additional issue of most of these association studies is that vitamin D levels were measured only once, which does not permit distinction between outcome and exposure. Indeed, some studies have reported low serum vitamin D as a result of malignancy ([@B82]).

Above-mentioned skin types, alimentary, and social habits yet do not fully explain vitamin D variability among populations ([@B83]). One major determinant of individual susceptibility to vitamin D is the activity of vitamin D metabolizing enzymes. Three major cytochrome P-450 (CYP) hydroxylases are responsible for vitamin D activation through 25- followed by 1α-hydroxylation of the molecule, and deactivation through 24-hydroxylation. Multiple enzymes have been reported as vitamin D 25-hydroxylases, a step occurring constitutively and primarily in the liver. Unlike 25-hydroxylation, 1α-hydroxylation of 25(OH)D~3~ by the CYP27B1 is a tightly regulated and rate-limiting step. It is regulated by calcium, 1α,25(OH)~2~D~3~ itself, PTH, calcitonin, and phosphate levels. Recently, fibroblast growth factor 23 (FGF23) was identified as a novel antagonist of PTH and is thought to play an important role in vitamin D regulation pathway ([@B84]). Although CYP27B1 and CYP24A1 are primarily expressed in the kidney, recent studies showed that they are expressed in many other tissues, including the thyroid ([@B61], [@B62]). In TC, there is evidence that polymorphisms leading to impaired CYP27B1 function and/or increased CYP24A1 activity are associated with increased TC risk ([@B49]). Transcriptional profiling studies show that both enzymes are overexpressed in early TC ([@B61]), but their expression tends to decrease along with tumor progression ([@B64], [@B66]).

Determinants of predicted response to vitamin D {#S3-5}
-----------------------------------------------

The action of vitamin D mainly occurs through binding to the VDR ([@B23]), whose levels are subject to genetic variations. Using the UCSC genomic database, we analyzed 552 thyroid samples that underwent genomic profiling using RNA Seq. The expression of VDR was down regulated in benign thyroid samples and up regulated in most TC cases (Figure [2](#F2){ref-type="fig"}). These results are confirmed by a few *in vitro* studies using TC cell lines ([@B72]) and independent clinical samples ([@B64], [@B66]). However, VDR levels alone may translate poorly with response to vitamin D stimulation if polymorphisms of VDR are not taken into account ([@B71], [@B85], [@B86]). The analysis of the genomic organization of the VDR *locus* at chromosome 12q13.1 revealed the large *VDR* gene (about 100 Kb) with an extensive promoter region capable of generating multiple tissue-specific transcripts ([@B87]). In view of the observed genome-wide frequency of single nucleotide polymorphisms ([@B88]), one can predict \>100 functional polymorphisms to be present in the VDR region alone, including the promoter region (Figure [3](#F3){ref-type="fig"}). Point mutations in the VDR gene have been identified in various regions, including the VDR DNA binding domain (DBD) and the ligand-binding domain (LBD) ([@B89]). Such mutations can disrupt ligand-binding affinity to the receptor ([@B90]), heterodimerization of VDR with RXR ([@B91]), or interactions of the VDR receptor with partners such as coactivators ([@B92]). Other mutations such as in the initiation codon can create a premature termination ([@B93]) or alternative translation start sites to result in alternative splicing and formation of truncated proteins ([@B94], [@B95]). The analysis of the COSMIC database showed a high proportion of missense mutations that were re-identified (67.44%), while complex mutations were not detected (Table [3](#T3){ref-type="table"}). The distribution of the mutations observed in the VDR gene in TC is shown in Figure [4](#F4){ref-type="fig"}. Only two studies investigated the association between VDR polymorphisms and TC risk, one showed an increased TC risk for patients with particular VDR polymorphism ([@B48]), while another could not point out any significant difference ([@B56]).

![**Gene expression profile showing VDR signature for 552 thyroid cancer cases (RNA Seq)**. Each row corresponds to sample from a single case. Columns from the left correspond to genomic heatmap according to chromosomal location. The last two columns represent VDR expression profile (represented by red for overexpression and green for downregulation) in normal (pink) versus cancer (red) tissues. VDR is mostly overexpressed in malignant samples but almost absent in benign tissues. Source: UC Santa Cruz -- Cancer Genomics Browser.](fonc-04-00309-g002){#F2}

![**Schematic diagram of VDR gene showing different restriction site on chromosome 12**.](fonc-04-00309-g003){#F3}

###### 

**Mutations identified in VDR**.

  Position (AA)   Mutation  (CDS)   Mutation (amino acid)                     Mutation  type
  --------------- ----------------- ----------------------------------------- -------------------------------
  8               c.23C \> T        p.T8I                                     Substitution -- missense
  33              c.98G \> A        p.G33D                                    Substitution -- missense
  52              c.156G \> A       p.M52I                                    Substitution -- missense
  74              c.221G \> A       p.R74H                                    Substitution -- missense
  78              c.233C \> G       p.A78G                                    Substitution -- missense
  130             c.389G \> A       p.R130H                                   Substitution -- missense
  146             c.438C \> G       p.T146T                                   Substitution -- coding silent
  149             c.445G \> T       p.D149Y                                   Substitution -- missense
  154             c.460C \> T       p.R154W                                   Substitution -- missense
  158             c.472C \> T       p.R158C                                   Substitution -- missense
  159             c.477G \> C       p.V159V                                   Substitution -- coding silent
  161             c.481G \> A       p.D161N                                   Substitution -- missense
  162             c.484G \> T       p.G162C                                   Substitution -- missense
  169             c.507G \> A       p.R169R                                   Substitution -- coding silent
  181             c.541G \> T       p.D181Y                                   Substitution -- missense
  191             c.573C \> A       p.I191I                                   Substitution -- coding silent
  199             c.597G \> A       p.S199S                                   Substitution -- coding silent
  208             c.623G \> T       p.S208I                                   Substitution -- missense
  236             c.708C \> A       p.Y236[^a^](#tfn5){ref-type="table-fn"}   Substitution -- nonsense
  253             c.757G \> T       p.D253Y                                   Substitution -- missense
  274             c.820C \> T       p.R274C                                   Substitution -- missense
  296             c.887G \> A       p.R296H                                   Substitution -- missense
  320             c.960G \> A       p.L320L                                   Substitution -- coding silent
  339             c.1015G \> A      p.V339I                                   Substitution -- missense
  350             c.1049C \> T      p.A350V                                   Substitution -- missense
  350             c.1050G \> A      p.A350A                                   Substitution -- coding silent
  352             c.1056T \> C      p.I352I                                   Substitution -- coding silent
  353             c.1058A \> T      p.E353V                                   Substitution -- missense
  358             c.1072C \> T      p.R358C                                   Substitution -- missense
  365             c.1094C \> T      p.T365M                                   Substitution -- missense
  368             c.1103G \> A      p.R368H                                   Substitution -- missense
  379             c.1135C \> T      p.L379F                                   Substitution -- missense
  399             c.1196A \> T      p.K399M                                   Substitution -- missense
  402             c.1205G \> C      p.R402P                                   Substitution -- missense
  418             c.1254G \> T      p.V418V                                   Substitution -- coding silent
  420             c.1258G \> A      p.E420K                                   Substitution -- missense

*^a^Nonsense mutation resulting in stop codon*.

![**Pie-chart showing the percentage of the mutation type in VDR in thyroid cancer according to COSMIC database**.](fonc-04-00309-g004){#F4}

Downstream impact of VDR activation {#S3-6}
-----------------------------------

Upon activation by vitamin D, VDR binds as a heterodimer with retinoid-X receptors to specific VDREs ([@B84]). VDREs usually bear a consensus sequence known as DR3 element located in the promoter region of the target genes. In addition to this classic mechanism, recent chromatin-immunoprecipitation (ChIP-seq) studies allowed to gain genome-wide insights of the binding sites of VDR ([@B96]). These studies showed that the ligand-bound heterodimer can bind to \~2000--8000 sites in the genome. Interestingly, the majority of the binding sites do not bear the classical DR3-type sequence ([@B84]). A significant enrichment was seen in regions associated with active chromatin and histone modifications thus supporting a broad genetic and epigenetic regulatory role of vitamin D. Further enrichment of VDR binding was also found in proximity of genes involved in autoimmune diseases (e.g., multiple sclerosis, type-I diabetes, and Crohn's disease) and colorectal or breast cancer ([@B97]). For TC, only data relying on classical *in vitro* experiments is available.

In agreement with experimental studies in other cancer types, exposure of a variety of TC cells to vitamin D *in vitro* leads to antiproliferative and pro-differentiation properties ([@B62], [@B63], [@B67], [@B70], [@B71], [@B73]) (Table [2](#T2){ref-type="table"}). These results have been confirmed by *in vivo* studies ([@B65], [@B68]). Most studies are testing vitamin D itself and synthetic vitamin D analogs, as patient's exposure to pharmacologically high doses of vitamin D can be limited by the side-effects, mainly hypercalcemia ([@B63], [@B67], [@B70], [@B71], [@B73]).

Mechanistically, vitamin D was shown to inhibit proliferation through c-mac mRNA inhibition, which is a well-known proto-oncogene ([@B70]). Further, it can induce a growth arrest effect in part through stimulating accumulation of the cyclin-dependent kinase inhibitor p27^kip1^ in the nucleus ([@B67]). Treatment with vitamin D is thought to prevent p27^kip1^ phosphorylation, which was shown to increase its ubiquitin-dependent proteasome degradation ([@B67]). Further, vitamin D was shown to enhance cell--cell adhesion through PTEN-dependent fibronectin upregulation ([@B68]). Those results could be confirmed *in vivo*. Interestingly, the antiproliferative effect of vitamin D was abolished when knocking down fibronectin ([@B68]) and was shown to be independent of CEACAM1 expression, a tumor-suppressive adhesion molecule ([@B69]).

Conclusion and Perspectives {#S4}
===========================

The pleiotropic roles of vitamin D in cancer have been recognized through seminal preclinical studies although the preventive and therapeutic potential of vitamin D or its analogs remain debated due in part to the complex mode of action of this vitamin. Recent progress in high-throughput technologies to interrogate human genomic and epigenomic events has provided additional levels of regulatory loops and individual genetic variations that can impact on individual susceptibility to vitamin D. This knowledge opens up new tools to address confounding factors that contribute to discrepant results seen in previous association studies, in particular in relation to cancer prevention. As well, this knowledge impels an exciting avenue in the discovery of novel vitamin D analogs with enhanced preventive or therapeutic efficiency and limited side-effects.
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